July 27, 2026 Thermo Fisher Scientific Showcases Innovations to Address Clinical Needs at ADLM 2026 At ADLM 2026, Thermo Fisher Scientific unveiled innovative diagnostic solutions, including the EXENT® Solution for myeloma and advancements in oncology and autoimmune disease testing. Their commitment to enhancing laboratory efficiency and patient care was evident through a range of new technologies and digital tools.
July 24, 2026 Thermo Fisher Scientific Launches InstaFlux for Food Microbiology Labs: A Game-Changer in Pathogen Testing Thermo Fisher Scientific has launched InstaFlux, an innovative media-on-demand workflow for food microbiology labs, designed to enhance efficiency and reduce costs. With rapid media preparation and significant labor savings, InstaFlux addresses key industry challenges while promoting sustainability. It is tailored for high-throughput labs facing increasing demands in pathogen testing.
July 23, 2026 Thermo Fisher Scientific Reports Strong Second Quarter Results for 2026 Thermo Fisher Scientific achieved significant growth in Q2 2026, with revenue increasing 10% to $11.99 billion and earnings per share rising by 9%. The company continues to innovate with new product launches and strategic partnerships, positioning itself for continued success in the life sciences sector.
July 09, 2026 Thermo Fisher Scientific Announces Quarterly Dividend Thermo Fisher Scientific has announced a quarterly cash dividend of $0.47 per share, payable on October 15, 2026. This decision highlights the company’s robust financial health and commitment to shareholder value, making it an attractive option for investors seeking stability.
July 07, 2026 Thermo Fisher Scientific Secures Groundbreaking FBI Approval for Rapid DNA Technology Thermo Fisher Scientific's RapidINTEL™ Plus Cartridge has received FBI approval, allowing law enforcement to rapidly generate DNA profiles from crime scene samples. This groundbreaking technology promises to expedite investigations, enhance public safety, and redefine forensic practices across the U.S.
July 01, 2026 Thermo Fisher Scientific Set to Announce Q2 Earnings on July 23, 2026 Thermo Fisher Scientific is set to release its Q2 2026 earnings on July 23, featuring a live conference call for investors. The company aims to provide insights into its financial performance and future guidance, emphasizing its leadership in scientific innovation.
June 01, 2026 Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma, and Applied Testing at ASMS 2026 At ASMS 2026, Thermo Fisher Scientific launched an expanded range of Orbitrap mass spectrometry platforms and AI-driven software aimed at advancing research, biopharmaceutical development, and environmental testing. Key innovations include the Tribrid Apex Mass Spectrometer and Excedion Mass Spectrometer, which enhance analytical capabilities and efficiency for complex sample analysis.
May 28, 2026 Thermo Fisher Scientific Unveils Next-Generation Innovations at ASMS 2026 Thermo Fisher Scientific unveiled advanced mass spectrometry innovations, including the Orbitrap Tribrid Apex and Excedion systems, at ASMS 2026. These technologies enhance drug discovery by providing faster, more sensitive analysis and robust data for regulatory compliance, driving forward the future of precision therapies.
May 20, 2026 Thermo Fisher Scientific Announces Quarterly Dividend: A Commitment to Shareholder Value Thermo Fisher Scientific has announced a quarterly cash dividend of $0.47 per share, payable on July 15, 2026, to shareholders recorded by June 15, 2026. This move underscores the company's strong financial position and commitment to providing value to its investors while continuing to lead in scientific innovation.
May 20, 2026 Thermo Fisher Scientific Showcases Robust Growth and Innovation at 2026 Investor Day Thermo Fisher Scientific's 2026 Investor Day highlighted the company's commitment to innovation and operational excellence. CEO Marc Casper emphasized their growth strategy, including AI integration and disciplined capital deployment, ensuring robust future performance.
May 06, 2026 Thermo Fisher Scientific Inc. Secures Leadership Position in ISG Provider Lens™ Report Thermo Fisher Scientific Inc. has been named a Leader among CROs in the 2026 ISG Provider Lens™ report, highlighting its commitment to digital innovation and AI in clinical trials. The report praises the company's strategies for patient engagement and advancements in pharmacovigilance, solidifying its position as a pioneer in life sciences.
May 04, 2026 Thermo Fisher Scientific Unveils Innovative Bioreactor for Cell Therapy Manufacturing Thermo Fisher Scientific has launched the CTS DynaXS Single Use Bioreactor, aimed at improving scalable manufacturing processes for cell therapies. This innovative platform addresses the industry's need for automation-ready systems and supports the transition from research to clinical development.
May 01, 2026 Thermo Fisher Scientific Inc. Reports Strong Q1 2026 Results Amid Mixed Market Conditions Thermo Fisher Scientific reported robust Q1 2026 results with revenues rising to $11 billion, driven by growth in Life Sciences Solutions. However, challenges in Analytical Instruments and Specialty Diagnostics were noted. The company remains optimistic about future growth through strategic investments.
April 28, 2026 Thermo Fisher Scientific Unveils Flagship Bioprocess Design Center in Massachusetts Thermo Fisher Scientific has opened a new Bioprocess Design Center in Plainville, Massachusetts, aimed at enhancing biologics development. The center features advanced facilities and collaborative expertise to accelerate the production of innovative therapies, contributing to the state's economy and leadership in life sciences.
April 28, 2026 Thermo Fisher Scientific to Hold 2026 Investor Day: A Look Ahead Thermo Fisher Scientific will hold its Investor Day on May 20, 2026, in New York City, showcasing its strategic direction and operational performance. The event will include presentations from senior management and a Q&A session. A live webcast will be available for those unable to attend.
April 27, 2026 Thermo Fisher Scientific Sells Microbiology Business to Astorg for $1.075 Billion Thermo Fisher Scientific has signed a deal to sell its microbiology business to Astorg for $1.075 billion to enhance shareholder value. This strategic move allows Thermo Fisher to focus on its core competencies and pursue new growth opportunities, with the transaction expected to close in late 2026.
April 23, 2026 Thermo Fisher Scientific Reports Strong First Quarter 2026 Results Thermo Fisher Scientific's Q1 2026 results show a revenue increase of 6% to $11.01 billion, boosted by innovative product launches and strategic collaborations. The company remains optimistic about its growth trajectory and continues to prioritize shareholder value.
April 09, 2026 Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Thermo Fisher Scientific has partnered with PRECISE for the PRECISE-SG100K study, enhancing population-scale proteomics. This collaboration aims to advance disease biology understanding and precision medicine through innovative technologies and comprehensive data analysis.
April 01, 2026 Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development Thermo Fisher Scientific has launched the Gibco CHOvantage GS Cell Line Development Kit, designed to expedite biologics development. This innovative platform allows researchers to produce high-performing CHO cell lines efficiently, addressing industry challenges while maintaining regulatory compliance.
April 01, 2026 Thermo Fisher Scientific Set to Release Q1 2026 Financial Results Thermo Fisher Scientific will release its Q1 2026 financial results on April 23, 2026, followed by a conference call at 8:30 a.m. ET. Investors can access the call via webcast or phone to hear insights on performance and future strategies.
March 31, 2026 Thermo Fisher Scientific Unveils Next-Generation Glacios 3 Cryo-TEM Thermo Fisher Scientific has launched the Glacios 3 Cryo-TEM, a next-generation cryo-electron microscope that enhances structural biology research. With advanced imaging capabilities and AI-powered workflows, it promises to democratize access to cryo-EM technology, significantly impacting drug development.
March 25, 2026 Thermo Fisher Scientific Partners with SHL Medical to Enhance Drug-Device Solutions Thermo Fisher Scientific has partnered with SHL Medical to expand its drug-device solutions, enhancing its Ridgefield facility's capacity for autoinjectors and sterile manufacturing. This collaboration aims to meet the rising demand for self-administered therapies, streamlining the production process and supporting efficient delivery of critical treatments.
March 24, 2026 Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc. Thermo Fisher Scientific has finalized its acquisition of Clario Holdings for $8.875 billion, enhancing its clinical research capabilities. The deal is expected to drive innovation and efficiency in drug development, contributing positively to Thermo Fisher's financial performance.
March 05, 2026 Thermo Fisher Scientific Opens Bay Area Cryo-EM Drug Discovery Center to Accelerate Breakthrough Therapies Thermo Fisher Scientific has launched a new Cryo-EM Drug Discovery Center in South San Francisco to accelerate the development of life-saving therapies. The facility provides access to advanced cryo-EM technologies, promising improved clinical success rates and reduced costs for drug discovery. Collaboration with pharmaceutical innovators is emphasized to enhance therapeutic development.
March 02, 2026 Thermo Fisher Scientific Launches Innovative Chromogenic Culture Media to Combat Candida Infections Thermo Fisher Scientific has launched two new chromogenic culture media, Brilliance Candida 2 Agar and Spectra Candida Agar, to improve the detection of Candida species, including drug-resistant Candida auris. These products aim to support faster diagnosis and effective infection control strategies in the face of rising healthcare challenges posed by invasive fungal infections.
February 26, 2026 Thermo Fisher Scientific Launches TacroType™ Test to Enhance Transplant Patient Care Thermo Fisher Scientific has launched the TacroType test to improve tacrolimus dosing for transplant patients. This pharmacogenetic test analyzes genetic variations to tailor medication dosages, enhancing patient outcomes and minimizing complications.
February 26, 2026 Thermo Fisher Scientific Inc. Reports Strong Growth in 2025 Annual Report Thermo Fisher Scientific Inc.'s 2025 annual report highlights robust revenue growth, achieving $44.55 billion. The company focuses on innovation and strategic acquisitions to enhance its market position while returning value to shareholders.
February 25, 2026 Thermo Fisher Scientific Announces Increased Quarterly Dividend Thermo Fisher Scientific has raised its quarterly dividend by 10% to $0.47, affirming its strong financial health and commitment to shareholders. The increase, effective April 15, 2026, showcases the company's confidence in ongoing growth and innovation in the scientific sector.
February 24, 2026 Thermo Fisher Scientific to Showcase Leadership at Upcoming Investor Conference Thermo Fisher Scientific's CEO, Marc N. Casper, will present at the Raymond James Annual Institutional Investors Conference on March 3, 2026. The company aims to provide insights into its growth strategies and market positioning as a leader in scientific services with over $40 billion in annual revenue.
February 11, 2026 Thermo Fisher Scientific Expands Real-World Data Interoperability Through Strategic Collaboration with Datavant Thermo Fisher Scientific has partnered with Datavant to enhance real-world data integration in clinical research, aiming to improve patient outcomes and streamline evidence generation. This collaboration will leverage Datavant's secure data technology to provide biopharmaceutical clients with advanced analytics and linked patient data.
February 10, 2026 Thermo Fisher Scientific Inc. Announces Senior Notes Offering Thermo Fisher Scientific has announced a $3.8 billion offering of senior notes to finance its acquisition of Clario Holdings. The offering includes various tranches with distinct maturities and interest rates, reflecting Thermo Fisher's strategy for growth in the life sciences sector.
January 29, 2026 Thermo Fisher Scientific Reports Strong 2025 Results with Promising Outlook for 2026 Thermo Fisher Scientific reported a 7% revenue growth in Q4 2025, reaching $12.21 billion, and a 4% increase for the full year. The company attributes its success to strategic innovations and plans an optimistic outlook for 2026.
January 13, 2026 Nalgene Outdoor Launches Vibrant New Collection: Thrill & Motion Nalgene Outdoor has launched the Thrill & Motion collection, featuring colorful, sustainable bottles designed for active lifestyles. The collection emphasizes both functionality and aesthetics, making it perfect for outdoor enthusiasts and everyday users alike.
January 12, 2026 Thermo Fisher Scientific Partners with NVIDIA to Revolutionize Laboratory Automation through AI Thermo Fisher Scientific has partnered with NVIDIA to integrate AI into laboratory automation, improving workflow efficiency and accuracy in scientific research. This collaboration aims to create a unified platform for data and instruments, empowering researchers to achieve faster, more impactful discoveries.
January 06, 2026 Thermo Fisher Scientific to Share Insights at J.P. Morgan 2026 Healthcare Conference Thermo Fisher Scientific's CEO, Marc N. Casper, will present at the J.P. Morgan 2026 Healthcare Conference, discussing the company's strategic vision in healthcare. A live webcast will be available for stakeholders to access insights post-presentation.
January 06, 2026 Thermo Fisher Scientific Launches Groundbreaking Obesity Registry Thermo Fisher Scientific has launched the PPD™ CorEvitas™ Obesity Registry to gather real-world data on obesity treatment effectiveness and patient experiences. This initiative aims to enhance understanding and management of obesity by providing valuable insights for healthcare professionals and researchers.
December 26, 2025 Thermo Fisher Scientific Set to Reveal Q4 and Full-Year 2025 Financial Results Thermo Fisher Scientific will host an earnings conference call on January 29, 2026, to discuss its financial performance for Q4 2025. The call will provide insights on revenue and future strategies aimed at sustaining growth. Access details for the live call and replay are included.
December 18, 2025 Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer’s Disease Registry to Advance Real-World Evidence in Neurodegenerative Care Thermo Fisher Scientific has launched the PPD CorEvitas Alzheimer’s Disease Registry to collect real-world data on drug safety and effectiveness. This initiative aims to address the growing public health challenge posed by Alzheimer’s disease by fostering collaboration and enhancing understanding of treatment outcomes.
December 15, 2025 OlivePoint Capital Expands Portfolio with Strategic Acquisition in Raleigh-Durham OlivePoint Capital, in partnership with Redwood Capital Management, has acquired a 220,000-square-foot office building in Raleigh-Durham, fully leased to PPD. This strategic move leverages current market conditions to capitalize on high-quality assets in a rapidly growing innovation hub.
December 02, 2025 Thermo Fisher Scientific Expands Bioprocessing Capabilities in Asia Thermo Fisher Scientific has announced the expansion of its bioprocessing capabilities in Asia, establishing new centers in Hyderabad and enhancing facilities in Incheon and Singapore. This strategic move aims to support the growing demand for biologics and advanced therapies in the biopharmaceutical sector, fostering innovation and efficiency in biomanufacturing.
November 25, 2025 Thermo Fisher Scientific Announces Pricing of €2.1 Billion Euro-Denominated Senior Notes Thermo Fisher Scientific has priced €2.1 billion in euro-denominated senior notes, aimed at boosting financial flexibility and funding growth initiatives. The offering includes floating and fixed rate notes, with proceeds allocated for acquisitions, debt management, and other corporate purposes.
November 18, 2025 Thermo Fisher Scientific Launches Advanced Therapies Collaboration Center in Philadelphia Thermo Fisher Scientific has opened its Advanced Therapies Collaboration Center in Philadelphia, aimed at supporting the development of cell and gene therapies. This facility enhances collaboration within the biotech ecosystem, providing vital resources to innovators and streamlining the path from research to clinical application.
November 17, 2025 Thermo Fisher Scientific Launches CorEvitas Clinical Registry for Myasthenia Gravis Thermo Fisher Scientific has launched the CorEvitas Myasthenia Gravis Registry to collect critical data on this rare autoimmune disorder. The initiative aims to enhance understanding of MG's progression and improve treatment strategies through patient-centered research.
November 06, 2025 Thermo Fisher Scientific Declares Quarterly Dividend: A Commitment to Shareholder Value Thermo Fisher Scientific has declared a quarterly dividend of $0.43 per share, set to be paid on January 15, 2026. This move highlights the company's strong financial health and dedication to returning value to shareholders while maintaining its leadership in scientific services.
November 06, 2025 Thermo Fisher Scientific Announces $5 Billion Share Repurchase Program Thermo Fisher Scientific has authorized a $5 billion share repurchase program, aiming to boost shareholder value and signal its financial health. This strategic move underscores the company's commitment to innovation and market leadership.
October 31, 2025 Thermo Fisher Scientific Inc. Reports Strong Q3 2025 Results Amid Market Challenges Thermo Fisher Scientific Inc. reported a revenue increase to $11.12 billion in Q3 2025 despite challenges in the academic and government sectors. The company continues to focus on strategic acquisitions and innovation to enhance market positioning.
October 29, 2025 Thermo Fisher Scientific to Acquire Clario Holdings for $8.875 Billion Thermo Fisher Scientific has agreed to acquire Clario Holdings for $8.875 billion to bolster its clinical trial data solutions. This strategic move aims to enhance drug development through improved digital insights and integration of endpoint data, ultimately benefiting pharmaceutical companies and patients alike.
October 28, 2025 Thermo Fisher Scientific Unveils Helios MX1 PFIB-SEM: A Game Changer for Semiconductor Manufacturing Thermo Fisher Scientific has launched the Helios MX1 PFIB-SEM, a groundbreaking tool for semiconductor manufacturing that allows real-time, atomic-level analysis. This innovation enhances productivity, accelerates time-to-yield, and has far-reaching implications across various industries, including consumer electronics and AI.
October 27, 2025 Thermo Fisher Scientific Unveils Advancements in Drug Development at CPHI Frankfurt 2025 At CPHI Frankfurt 2025, Thermo Fisher Scientific highlights its innovative drug development solutions, including the AI-driven OSDPredict™ and strategic collaborations. The company focuses on enhancing scalability and efficiency in biopharmaceutical manufacturing.
October 23, 2025 Thermo Fisher Scientific Unveils Groundbreaking Mass Detector for Environmental and Food Safety Thermo Fisher Scientific has launched the Orbitrap Exploris EFOX Mass Detector, a groundbreaking tool for environmental and food safety testing. This system enhances detection capabilities for PFAS and other contaminants, streamlines workflows, and ensures regulatory compliance, making it essential for modern laboratories.
October 22, 2025 Thermo Fisher Scientific Reports Strong Third Quarter Results for 2025 Thermo Fisher Scientific reported impressive Q3 2025 results, highlighting a 5% revenue growth to $11.12 billion and significant advancements in precision medicine and innovative product launches. The company's strategic collaborations and acquisitions further reinforce its market leadership and commitment to innovation.
October 21, 2025 Thermo Fisher Scientific Launches Innovative Carbon Calculator to Drive Greener Clinical Trials Thermo Fisher Scientific has launched a Clinical Trial Carbon Calculator to help biopharmaceutical companies estimate and reduce the carbon footprint of clinical trials. This open-access tool aims to promote sustainability and empower research sponsors to make environmentally responsible decisions.
October 16, 2025 Thermo Fisher Scientific Partners with OpenAI to Transform Drug Development Thermo Fisher Scientific has partnered with OpenAI to innovate drug development by integrating AI across its operations. This collaboration aims to streamline clinical research and optimize resource allocation, ultimately speeding up the delivery of new medicines to patients.
October 15, 2025 Thermo Fisher Scientific Fuels the Future of Multi-Omics Research Thermo Fisher Scientific has launched the SwiftArrayStudio Microarray Analyzer, revolutionizing multi-omics research with integrated genotyping processes. This innovative tool enhances efficiency, reduces turnaround time, and supports new research opportunities, particularly in pharmacogenomics and precision medicine.
October 01, 2025 Thermo Fisher Scientific Inc. Prices $2.5 Billion Offering of Senior Notes Thermo Fisher Scientific has priced a $2.5 billion offering of senior notes to strengthen its financial flexibility. The proceeds will support acquisitions, debt repayment, and capital expenditures, positioning the company for future growth.
October 01, 2025 Thermo Fisher Scientific and AstraZeneca Forge R&D Alliance to Propel Life Science Innovation Thermo Fisher Scientific and AstraZeneca have announced a strategic R&D partnership to drive innovation in life sciences. Focused on chromatography, molecular genomics, and proteomics, this collaboration aims to enhance drug development and support biotech companies globally.
October 01, 2025 Thermo Fisher Scientific Set to Release Q3 Earnings on October 22, 2025 Thermo Fisher Scientific is set to release its Q3 earnings before market open on October 22, 2025. A conference call will follow at 8:30 a.m. ET, providing insights into the company's performance and future strategies.
September 30, 2025 Thermo Fisher Scientific Unveils Innovative Connect Platform at Lab of the Future Europe Thermo Fisher Scientific debuted its innovative Connect Platform at the Lab of the Future Europe conference, aimed at driving digital transformation in laboratories. The platform helps scientists enhance productivity and focuses on impactful discoveries amidst growing digital needs. Additionally, a strategic partnership with BenchSci was announced to further develop AI-driven research tools.
September 25, 2025 Thermo Fisher Scientific Partners with Dr. Park CDMO to Enhance Viral Vector Manufacturing Thermo Fisher Scientific is collaborating with Dr. Park CDMO to enhance viral vector manufacturing capabilities in South Korea. This partnership aims to accelerate the production of cell and gene therapies, addressing the rising global demand for therapeutics.
September 22, 2025 Thermo Fisher Scientific Unveils the Hypulse Surface Analysis System: A New Era for Material Science Thermo Fisher Scientific has launched the Hypulse Surface Analysis System, revolutionizing XPS depth-profiling for material scientists. Featuring femtosecond laser technology, this system enhances accuracy and speeds up data collection across various industries, from medical implants to energy solutions.
August 01, 2025 Thermo Fisher Scientific Inc. Reports Mixed Results in Q2 2025 Thermo Fisher Scientific's Q2 2025 results show a 2.94% revenue increase to $10.85 billion, propelled by strong demand in pharmaceuticals and biotech. However, challenges in academic and industrial sectors, particularly in China, highlight the company's need for strategic adaptability.
May 06, 2025 Thermo Fisher Scientific Set to Present at BofA Securities Health Care Conference Thermo Fisher Scientific's CEO, Marc N. Casper, will present at the BofA Securities Health Care Conference on May 13, 2025. The presentation will offer insights into the company's strategies and performance in the health care sector, with a live webcast available for investors and analysts.
May 02, 2025 Thermo Fisher Scientific Inc. Reports Steady Growth in Q1 2025 Amid Market Challenges Thermo Fisher Scientific's Q1 2025 report shows modest revenue growth of $10.36 billion amid market challenges. Key drivers include strong performance in pharmaceuticals and international markets, despite declines in COVID-19 related sales.
April 24, 2025 Thermo Fisher Scientific Announces $2 Billion Investment to Bolster U.S. Innovation and Manufacturing Thermo Fisher Scientific is set to invest $2 billion in the U.S. over the next four years, focusing on manufacturing and R&D. This commitment aims to bolster the healthcare supply chain and support domestic biopharma development.
April 23, 2025 Thermo Fisher Scientific Reports Strong First Quarter 2025 Results Thermo Fisher Scientific's Q1 2025 results demonstrate resilience with $10.36 billion in revenue and a 15% increase in EPS. The company focuses on innovation, strategic partnerships, and shareholder returns, ensuring ongoing growth amidst economic uncertainties.
April 01, 2025 Thermo Fisher Scientific Set to Announce Q1 2025 Earnings Thermo Fisher Scientific is set to announce its Q1 2025 earnings on April 23, 2025, before market opening. The company will hold a conference call at 8:30 a.m. ET to discuss financial performance and outlook, amidst growing anticipation from analysts and investors.
March 03, 2025 SWOT Analysis of Thermo Fisher Scientific Inc. in 2025 This article provides a comprehensive SWOT analysis of Thermo Fisher Scientific Inc. in 2025. It outlines the company's strengths such as a strong market position and robust R&D, while also addressing weaknesses, opportunities for growth, and potential threats in the competitive landscape.
February 25, 2025 Thermo Fisher Scientific to Acquire Solventum’s Purification and Filtration Business Thermo Fisher Scientific has agreed to acquire Solventum's Purification & Filtration business for $4.1 billion, enhancing its bioprocessing portfolio. The acquisition aligns with Thermo Fisher's growth strategy, promising significant financial returns and operational synergies.
February 24, 2025 Thermo Fisher Scientific Set to Present at TD Cowen Health Care Conference Marc N. Casper, CEO of Thermo Fisher Scientific, will present at the TD Cowen Health Care Conference on March 3, 2025. The event highlights the company's role and strategies in advancing healthcare.
February 20, 2025 Thermo Fisher Scientific Inc. Reports Mixed Results in 2024 Annual Report Thermo Fisher Scientific Inc. reported a slight revenue increase for 2024 amid declining demand for COVID-19 products. The company continues to invest in innovation and strategic acquisitions, despite facing challenges in specific segments and geographical markets. Future growth will depend on how it navigates these changes.
February 19, 2025 Thermo Fisher Scientific Boosts Shareholder Returns with Dividend Increase Thermo Fisher Scientific announced a 10% increase in its quarterly dividend, raising it to $0.43 per share, effective April 15, 2025. This move underscores the company’s financial stability and commitment to enhancing shareholder value amidst ongoing growth strategies.
February 19, 2025 Thermo Fisher Scientific Appoints New Director to Board Thermo Fisher Scientific has appointed Karen S. Lynch to its board of directors, expanding its leadership team. With over 30 years in health care, Lynch brings valuable experience from her previous roles at CVS Health and Aetna, promising to enhance the company's strategic direction.
November 01, 2024 Thermo Fisher Scientific Inc. Reports Mixed Results for Q3 2024 Thermo Fisher Scientific reported mixed results for Q3 2024, with revenues of $10.59 billion but a decline in net income to $1.63 billion. Key segments showed varied performance, influenced by market demand shifts and strategic investments. The company remains focused on innovation and growth despite facing challenges in the post-COVID landscape.
August 02, 2024 Thermo Fisher Scientific Inc. Reports Q2 2024 Results: A Shift in Demand Thermo Fisher Scientific's Q2 2024 report shows a 2% revenue decline, driven by reduced COVID-19 product demand. Despite challenges, strategic acquisitions and strong liquidity signal potential for future growth.
May 03, 2024 Thermo Fisher Scientific Inc. Reports Q1 2024 Earnings: A Challenging Start to the Year Thermo Fisher Scientific's Q1 2024 earnings report shows a revenue decline to $10.34 billion, primarily due to decreased COVID-19 product demand. Despite challenges, the company maintains a solid balance sheet and strategic growth plans through acquisitions.
